The first and only FDA-approved pill proven to increase a woman’s sex drive.

All of the 8 RCTs included in this meta-analysis were phase 3 studies. Six studies were conducted among premenopausal women;[18–22,25] and 2 among postmenopausal women. [23,24] In one study, the women with HSDD who showed a predefined response to flexible-dose flibanserin (50 mg or 100 mg/d) during a 24-week open-label period were randomized to either flibanserin or placebo for the double-blind period. [19] In other studies, study subjects never took flibanserin before the randomization. Three studies used flibanserin 100 mg every night at bedtime, and one used flibanserin 50 to 100 mg every night at bedtime in the single intervention arm; these intervention arms were grouped as flibanserin 100 mg.[19,20,23,24] Two studies had 2 intervention arms and used flibanserin 50 mg every night at bedtime (grouped as flibanserin 50 mg) and flibanserin 100 mg every night at bedtime (grouped as flibanserin 100 mg). [18,22] One study had 3 intervention arms and used flibanserin 25 mg twice a day (omitted from the analysis), flibanserin 50 mg every night at bedtime (grouped as flibanserin 50 mg), and flibanserin 50 mg twice a day (grouped as flibanserin 100 mg). [21] The remaining study also had 3 intervention arms: flibanserin 25 mg twice a day (grouped as flibanserin 50 mg), flibanserin 50 mg twice a day (omitted from the analysis), and flibanserin 100 mg every night at bedtime (grouped as flibanserin 100 mg).

prescriptions written for Addyi*

Forest plot highlighting the (A) Change from baseline in PGI-I score in postmenopausal women, Flibanserin 100 mg vs Placebo; (B) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 100 mg vs Placebo; (C) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 50 mg vs Placebo; (D) Proportions of premenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo; (E) Proportions of premenopausal women responded positively at PBE, Flibanserin 50 mg vs Placebo; (F) Proportions of postmenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo. The percentage of premenopausal women who responded positively (“yes”) when asked whether they had experienced a meaningful benefit from the study medication was higher in the flibanserin 100 mg arm (OR 1.76, 95% CI [1.34, 2.31], P < .0001, I2 = 59% [moderate heterogeneity]) (Fig. For the same outcome, flibanserin 100 mg was better than placebo in postmenopausal women (OR 1.54, 95% CI [1.24, 1.90], P < .0001, I2 = 0% [not important heterogeneity]) (Fig. The safety outcomes of flibanserin versus placebo are summarized in Table 3. The number of study subjects experiencing any AEs was higher in the flibanserin 100 mg arm (RR 1.37, 95% CI [1.14, 1.65], P = .009, I2 = 93% [high heterogeneity], very low certainty of evidence), and flibanserin 50 mg arm (RR 1.18, 95% CI [1.03, 1.36], P = .02, I2 = 72% [moderate heterogeneity]) (Fig.

Concomitant Strong or Moderate CYP3A4 Inhibitor Use

More study subjects on flibanserin 100 mg experienced drug-related AEs (RR 2.33, 95% CI [1.96, 2.76], P < .00001, I2 = 0% [not important heterogeneity]) and AEs leading to study discontinuation (RR 2.08, 95% CI [1.39, 3.10], P = .0003, I2 = 50% [moderate heterogeneity]) than those on placebo. Serious AEs and severe AEs were comparable between flibanserin and placebo groups. Table 3 - The results of safety outcomes of flibanserin vs placebo in the meta-analysis. More subjects taking flibanserin 100 mg (RR 3.95, 95% CI [2.40, 6.51], P < .00001, I2 = 70% [moderate heterogeneity], low certainty of evidence) and flibanserin 50 mg (RR 2.39, 95% CI [1.61, 3.55], P < .0001, I2 = 0% [not important heterogeneity]) experienced dizziness than those who took a placebo. All the studies were of 24-week duration. Along with other outcomes, SSE was one of the primary outcomes of all the included studies. The details of the included and excluded studies are shown in Tables 1 and 2, respectively. Table 1 - The basic characteristics of the included randomized controlled trials and participants. NCT00360529, VIOLET Study, United States and Canada eDiary = electronic diary, FSFI-d = Female Sexual Function Index Desire Domain, HSDD = Hypoactive Sexual Desire Disorder, SSE = satisfying sexual events. Table 2 - The basic characteristics of the excluded published articles and participants.

- Open-label extension study of previous 5 clinical trials. - Somnolence, sedation, fatigue, dizziness, nausea, and vomiting were reported by 15.8%, 1.6%, 7.6%, 6.9%, 6.3%, and 1.4% of participants, respectively. - At study end, 42% of baseline non-remitters had improved man up pills their FSFI score to remission level.

Side effects

Table 1 - The basic characteristics of the included randomized controlled trials and participants. NCT00360529, VIOLET Study, United States and Canada eDiary = electronic diary, FSFI-d = Female Sexual Function Index Desire Domain, HSDD = Hypoactive Sexual Desire Disorder, SSE = satisfying sexual events. Table 2 - The basic characteristics of the excluded published articles and participants. - Open-label extension study of previous 5 clinical trials. - Somnolence, sedation, fatigue, dizziness, nausea, and vomiting were reported by 15.8%, 1.6%, 7.6%, 6.9%, 6.3%, and 1.4% of participants, respectively.

storage temp.

- At study end, 42% of baseline non-remitters had improved man up pills their FSFI score to remission level. Risk of bias in the included studies The bias risk across the 8 studies included in the meta-analysis is depicted in Figure S1, Supplemental Digital Content, All 8 studies (100%) exhibited low risks of performance bias, detection bias, and reporting bias; all (100%) had a high risk of other biases. Six studies (75%) exhibited low risks of selection bias, and 2 (25%) exhibited unclear risks. Regarding attrition bias, 5 studies (62.5%) showed low risks, and 3 (37.5%) exhibited unclear risks. Publication bias was assessed through funnel plots given in Figure S2, Supplemental Digital Content, The grades for the certainty of the evidence of the key outcomes of this meta-analysis are given in the SoF table (Table S1, Supplemental Digital Content, Effect of flibanserin on the primary efficacy outcomes In premenopausal women, flibanserin was superior to placebo in increasing the number of SSE at both 100 mg (MD 0.69, 95% CI [0.39, 0.99], P < .00001, I2 = 27% [mild heterogeneity], moderate certainty of evidence) (Fig. Risk of bias in the included studies The bias risk across the 8 studies included in the meta-analysis is depicted in Figure S1, Supplemental Digital Content, All 8 studies (100%) exhibited low risks of performance bias, detection bias, and reporting bias; all (100%) had a high risk of other biases. Six studies (75%) exhibited low risks of selection bias, and 2 (25%) exhibited unclear risks. Regarding attrition bias, 5 studies (62.5%) showed low risks, and 3 (37.5%) exhibited unclear risks.

• Flibanserin should be discontinued if no benefit is observed after several weeks.
• The medication's influence on mental health conditions is still being studied.
• Flibanserin was recognized as a breakthrough therapy for female sexual desire issues.
• Its use is guided by strict medical protocols due to safety concerns.
• Women are encouraged to report any adverse effects during treatment.
• Continued research aims to improve treatment options for female sexual health.
• Flibanserin is one of a few FDA-approved drugs for Female Sexual Desire Disorder.
• Clinical improvements may include increased frequency of satisfying sexual events.
• The drug's use should be combined with counseling when appropriate.

Publication bias was assessed through funnel plots given in Figure S2, Supplemental Digital Content, The grades for the certainty of the evidence of the key outcomes of this meta-analysis are given in the SoF table (Table S1, Supplemental Digital Content, Effect of flibanserin on the primary efficacy outcomes In premenopausal women, flibanserin was superior to placebo in increasing the number of SSE at both 100 mg (MD 0.69, 95% CI [0.39, 0.99], P < .00001, I2 = 27% [mild heterogeneity], moderate certainty of evidence) (Fig. In postmenopausal women, the superiority of flibanserin 100 mg over placebo in increasing the number of SSE was also observed (MD 0.37, 95% CI [0.14, 0.61], P = .002, I2 = 0% [not important heterogeneity], high certainty of evidence) (Fig.

Proper use of flibanserin

As Seen In

Sensitivity analysis performed by omitting each trial to search for the sources of heterogeneity of flibanserin 100 mg on SSE in premenopausal women showed that none of the trials could substantially influence the pooled effect. Forest plot highlighting the change from baseline in (A) SSE in premenopausal women, Flibanserin 100 mg vs Placebo; (B) SSE in premenopausal women, Flibanserin 50 vardenafil canada mg vs Placebo; (C) SSE in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) e-Diary sexual desire score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) e-Diary sexual desire score in premenopausal women, Flibanserin 50 mg vs Placebo. 3.5.2. eDiary sexual desire score Flibanserin 100 mg outperformed placebo in improving sexual desire score measured using eDiary (MD 1.71, 95% CI [0.43, 2.98], P = .009, I2 = 0% [not important heterogeneity], moderate certainty of evidence) (Fig.

• Flibanserin acts as an agonist on dopamine receptors and antagonist on certain serotonin receptors.
• The medication can take several weeks to show benefits.
• It is not approved for use in postmenopausal women.
• Flibanserin was initially developed as an antidepressant.
• It has a pharmacokinetic profile with a half-life of around 13 hours.
• Dose adjustments are necessary for patients with liver impairment.
• The drug can cause hypotension, especially with alcohol or CYP3A4 inhibitors.
• Patients are monitored for side effects such as sleepiness and low blood pressure.
• Flibanserin's efficacy is moderate and varies among women.

Such benefit was not observed with flibanserin 50 mg over placebo (MD 0.67, 95% CI [−0.71, 2.05], P = .34, I2 = 0% [not important heterogeneity]) (Fig.

What special precautions should I follow?

IN CLINICAL TRIALS1, WOMEN ON ADDYI EXPERIENCED:

Effect of flibanserin on secondary efficacy outcomes Compared to placebo, greater increments in FSFI desire domain scores were observed in premenopausal women with flibanserin 100 mg (MD 0.30, 95% CI [0.29, 0.31], P < .00001, I2 = 0% [not important heterogeneity]) (Fig.

• Flibanserin was one of the first drugs approved specifically for female hypoactive sexual desire.
• The drug's mechanism is different from that of PDE5 inhibitors used in men.
• It can induce side effects like low blood pressure and syncope, requiring caution.
• Patients should be monitored regularly for adverse effects during therapy.
• Flibanserin's approval marked significant progress in women's sexual health.
• It should be used with caution in women on other serotonergic medications.
• The medication's safety profile is still under ongoing research.
• It is not indicated for women with a history of alcohol abuse.
• The benefits of flibanserin are generally seen as modest but meaningful for some women.

A similar benefit was observed with flibanserin 100 mg in postmenopausal women (MD 0.25, 95% CI [0.06, 0.44], P = .01, I2 = 0% [not important heterogeneity]) (Fig.

Forest plot highlighting the change from baseline in (A) FSFI-d score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSFI-d score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSFI-d score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSFI total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSFI total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSFI total score in postmenopausal women, Flibanserin 100 mg vs Placebo.

• Potential for negative publicity and stigma surrounding a "pink Viagra."
• Media coverage often oversimplifies its mechanism and expected results.
• Patient education is crucial to set realistic expectations about benefits.
• Support groups and online communities exist for women discussing HSDD treatment.
• Ongoing research continues to explore other pharmacologic targets for HSDD.
• Future developments may include new formulations or combination therapies.
• The approval of flibanserin spurred increased investment in female sexual health.
• It remains a subject of debate in medical ethics, women's health, and drug regulation.
• Prescribers should stay updated on post-marketing safety communications.

Flibanserin 100 mg was better than placebo in improving FSFI total scores in both premenopausal (MD 2.51, 95% CI [1.47, 3.55], P < .00001, I2 = 90% [high heterogeneity]) (Fig. 3D), and postmenopausal women (MD 1.42, 95% CI [0.56, 2.29], P = .001, I2 = 0% [not important heterogeneity]) (Fig. Such a beneficial effect was not observed with flibanserin 50 mg dose in premenopausal women (MD 0.74, 95% CI [−0.52, 1.99], P = .25, I2 = 80% [high heterogeneity]) (Fig. FSDS-R item 13 and total scores Flibanserin 100 mg also outperformed placebo in reducing FSDS-R Item 13 scores in both premenopausal (MD −0.30, 95% CI [−0.31, −0.29], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. 4A), and postmenopausal women (MD −0.20, 95% CI [−0.39, −0.01], P = .04, I2 = 0% [not important heterogeneity]) (Fig. The efficacy of flibanserin 50 mg in reducing FSDS-R Item 13 scores in premenopausal women was similar to placebo (MD −0.10, 95% CI [−0.29, 0.09], P = .31, I2 = 0% [not important heterogeneity]) (Fig.

Further reading

In postmenopausal women, the superiority of flibanserin 100 mg over placebo in increasing the number of SSE was also observed (MD 0.37, 95% CI [0.14, 0.61], P = .002, I2 = 0% [not important heterogeneity], high certainty of evidence) (Fig. Sensitivity analysis performed by omitting each trial to search for the sources of heterogeneity of flibanserin 100 mg on SSE in premenopausal women showed that none of the trials could substantially influence the pooled effect. Forest plot highlighting the change from baseline in (A) SSE in premenopausal women, Flibanserin 100 mg vs Placebo; (B) SSE in premenopausal women, Flibanserin 50 vardenafil canada mg vs Placebo; (C) SSE in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) e-Diary sexual desire score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) e-Diary sexual desire score in premenopausal women, Flibanserin 50 mg vs Placebo. 3.5.2. eDiary sexual desire score Flibanserin 100 mg outperformed placebo in improving sexual desire score measured using eDiary (MD 1.71, 95% CI [0.43, 2.98], P = .009, I2 = 0% [not important heterogeneity], moderate certainty of evidence) (Fig.

Black Box Warnings

Such benefit was not observed with flibanserin 50 mg over placebo (MD 0.67, 95% CI [−0.71, 2.05], P = .34, I2 = 0% [not important heterogeneity]) (Fig. Effect of flibanserin on secondary efficacy outcomes Compared to placebo, greater increments in FSFI desire domain scores were observed in premenopausal women with flibanserin 100 mg (MD 0.30, 95% CI [0.29, 0.31], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. A similar benefit was observed with flibanserin 100 mg in postmenopausal women (MD 0.25, 95% CI [0.06, 0.44], P = .01, I2 = 0% [not important heterogeneity]) (Fig. Forest plot highlighting the change from baseline in (A) FSFI-d score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSFI-d score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSFI-d score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSFI total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSFI total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSFI total score in postmenopausal women, Flibanserin 100 mg vs Placebo. Flibanserin 100 mg was better than placebo in improving FSFI total scores in both premenopausal (MD 2.51, 95% CI [1.47, 3.55], P < .00001, I2 = 90% [high heterogeneity]) (Fig. Forest plot highlighting the change from baseline in (A) FSDS-R Item 13 score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSDS-R Item 13 score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSDS-R Item 13 score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSDS-R total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSDS-R total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSDS-R total score in postmenopausal women, Flibanserin 100 mg vs Placebo. In premenopausal women, flibanserin was superior to placebo in reducing FSDS-R total scores at both 100 mg (MD −3.30, 95% CI [−3.37, −3.23], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. A similar benefit of flibanserin 100 mg over placebo was also observed in postmenopausal women (MD −2.42, 95% CI [−3.68, −1.16], P = .0002, I2 = 0% [not important heterogeneity]) (Fig.

Postmenopausal vardenafil oral women treated with flibanserin 100 mg showed a similar change in PGI-I score compared to those treated with placebo (MD −0.15, 95% CI [−0.44, 0.14], P = .32, I2 = 56% [moderate heterogeneity]) (Fig. In premenopausal women, a higher number of subjects achieved improvements in the PGI-I score in the flibanserin 100 mg arm (OR 1.93, 95% CI [1.58, 2.36], P < .00001, I2 = 32% [mild heterogeneity]) (Fig. Forest plot highlighting the (A) Change from baseline in PGI-I score in postmenopausal women, Flibanserin 100 mg vs Placebo; (B) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 100 mg vs Placebo; (C) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 50 mg vs Placebo; (D) Proportions of premenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo; (E) Proportions of premenopausal women responded positively at PBE, Flibanserin 50 mg vs Placebo; (F) Proportions of postmenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo. The percentage of premenopausal women who responded positively (“yes”) when asked whether they had experienced a meaningful benefit from the study medication was higher in the flibanserin 100 mg arm (OR 1.76, 95% CI [1.34, 2.31], P < .0001, I2 = 59% [moderate heterogeneity]) (Fig. For the same outcome, flibanserin 100 mg was better than placebo in postmenopausal women (OR 1.54, 95% CI [1.24, 1.90], P < .0001, I2 = 0% [not important heterogeneity]) (Fig.

The Big Pink Fight for the Little Pink Pill

All of the 8 RCTs included in this meta-analysis were phase 3 studies. Six studies were conducted among premenopausal women;[18–22,25] and 2 among postmenopausal women. [23,24] In one study, the women with HSDD who showed a predefined response to flexible-dose flibanserin (50 mg or 100 mg/d) during a 24-week open-label period were randomized to either flibanserin or placebo for the double-blind period. [19] In other studies, study subjects never took flibanserin before the randomization. Three studies used flibanserin 100 mg every night at bedtime, and one used flibanserin 50 to 100 mg every night at bedtime in the single intervention arm; these intervention arms were grouped as flibanserin 100 mg.[19,20,23,24] Two studies had 2 intervention arms and used flibanserin 50 mg every night at bedtime (grouped as flibanserin 50 mg) and flibanserin 100 mg every night at bedtime (grouped as flibanserin 100 mg).

What should I know about Addyi before using it?

[18,22] One study had 3 intervention arms and used flibanserin 25 mg twice a day (omitted from the analysis), flibanserin 50 mg every night at bedtime (grouped as flibanserin 50 mg), and flibanserin 50 mg twice a day (grouped as flibanserin 100 mg). [21] The remaining study also had 3 intervention arms: flibanserin 25 mg twice a day (grouped as flibanserin 50 mg), flibanserin 50 mg twice a day (omitted from the analysis), and flibanserin 100 mg every night at bedtime (grouped as flibanserin 100 mg). All the studies were of 24-week duration. Along with other outcomes, SSE was one of the primary outcomes of all the included studies. The details of the included and excluded studies are shown in Tables 1 and 2, respectively. The safety outcomes of flibanserin versus placebo are summarized in Table 3. The number of study subjects experiencing any AEs was higher in the flibanserin 100 mg arm (RR 1.37, 95% CI [1.14, 1.65], P = .009, I2 = 93% [high heterogeneity], very low certainty of evidence), and flibanserin 50 mg arm (RR 1.18, 95% CI [1.03, 1.36], P = .02, I2 = 72% [moderate heterogeneity]) (Fig. More study subjects on flibanserin 100 mg experienced drug-related AEs (RR 2.33, 95% CI [1.96, 2.76], P < .00001, I2 = 0% [not important heterogeneity]) and AEs leading to study discontinuation (RR 2.08, 95% CI [1.39, 3.10], P = .0003, I2 = 50% [moderate heterogeneity]) than those on placebo. Serious AEs and severe AEs were comparable between flibanserin and placebo groups. Table 3 - The results of safety outcomes of flibanserin vs placebo in the meta-analysis. More subjects taking flibanserin 100 mg (RR 3.95, 95% CI [2.40, 6.51], P < .00001, I2 = 70% [moderate heterogeneity], low certainty of evidence) and flibanserin 50 mg (RR 2.39, 95% CI [1.61, 3.55], P < .0001, I2 = 0% [not important heterogeneity]) experienced dizziness than those who took a placebo.

Other uses for this medicine

3D), and postmenopausal women (MD 1.42, 95% CI [0.56, 2.29], P = .001, I2 = 0% [not important heterogeneity]) (Fig. Such a beneficial effect was not observed with flibanserin 50 mg dose in premenopausal women (MD 0.74, 95% CI [−0.52, 1.99], P = .25, I2 = 80% [high heterogeneity]) (Fig. FSDS-R item 13 and total scores Flibanserin 100 mg also outperformed placebo in reducing FSDS-R Item 13 scores in both premenopausal (MD −0.30, 95% CI [−0.31, −0.29], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. 4A), and postmenopausal women (MD −0.20, 95% CI [−0.39, −0.01], P = .04, I2 = 0% [not important heterogeneity]) (Fig. The efficacy of flibanserin 50 mg in reducing FSDS-R Item 13 scores in premenopausal women was similar to placebo (MD −0.10, 95% CI [−0.29, 0.09], P = .31, I2 = 0% [not important heterogeneity]) (Fig.

Storage Class

Forest plot highlighting the change from baseline in (A) FSDS-R Item 13 score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSDS-R Item 13 score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSDS-R Item 13 score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSDS-R total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSDS-R total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSDS-R total score in postmenopausal women, Flibanserin 100 mg vs Placebo. In premenopausal women, flibanserin was superior to placebo in reducing FSDS-R total scores at both 100 mg (MD −3.30, 95% CI [−3.37, −3.23], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. A similar benefit of flibanserin 100 mg over placebo was also observed in postmenopausal women (MD −2.42, 95% CI [−3.68, −1.16], P = .0002, I2 = 0% [not important heterogeneity]) (Fig. Postmenopausal vardenafil oral women treated with flibanserin 100 mg showed a similar change in PGI-I score compared to those treated with placebo (MD −0.15, 95% CI [−0.44, 0.14], P = .32, I2 = 56% [moderate heterogeneity]) (Fig. In premenopausal women, a higher number of subjects achieved improvements in the PGI-I score in the flibanserin 100 mg arm (OR 1.93, 95% CI [1.58, 2.36], P < .00001, I2 = 32% [mild heterogeneity]) (Fig.